Publications by authors named "E Shteyer"
Aim: This retrospective study aimed to assess the efficacy of prophylactic antibiotics in preventing ascending cholangitis following Kasai portoenterostomy (KPE). Data from 72 patients treated across four tertiary centres in Israel from 2008 to 2018 were analysed.
Methods: Clinical and laboratory data were collected from biliary atresia (BA) diagnosis until liver transplantation (LT) or study completion.
Mitochondria dysfunction is implicated in cell death, inflammation, and autoimmunity. During viral infections, some viruses employ different strategies to disrupt mitochondria-dependent apoptosis, while others, including SARS-CoV-2, induce host cell apoptosis to facilitate replication and immune system modulation. Given mitochondrial DNAs (mtDNA) role as a pro-inflammatory damage-associated molecular pattern in inflammatory diseases, we examined its levels in the serum of COVID-19 patients and found it to be high relative to levels in healthy donors.
View Article and Find Full Text PDFBackground And Aims: An increase in the number of cases of acute hepatitis of unknown origin (HUO) in children was observed in 2021. Adenovirus and adeno-associated virus 2 (AAV2) infections have been suggested as possible triggers. However, the potential etiology is still unclear.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the effects of oral vancomycin on inflammatory bowel disease (IBD) in patients with primary sclerosing cholangitis (PSC) using data from the Paediatric PSC Consortium.
- A retrospective cohort of 113 PSC-IBD patients was analyzed, comparing 70 treated with vancomycin to 210 untreated ones, focusing on clinical remission after one year.
- Results show vancomycin significantly improves odds of both clinical and endoscopic remission, highlighting the need for further randomized controlled trials to confirm these findings and assess safety and dosing.
Background & Aims: PEDFIC 2, an ongoing, open-label, 72-week study, evaluates odevixibat, an ileal bile acid transporter inhibitor, in patients with progressive familial intrahepatic cholestasis.
Methods: PEDFIC 2 enrolled and dosed 69 patients across two cohorts; all received odevixibat 120 μg/kg per day. Cohort 1 comprised children from PEDFIC 1, and cohort 2 comprised new patients (any age).